Health tech companies made several major funding announcements in August, including Cityblock’s $116 million Series E round, Happy Health’s $75 million financing, Flagler Health’s $50 million Series B, and Network Bio’s $50 million launch funding, according to Dealbreaker.
Cityblock raises $116 million Series E tied to Homeward Health acquisition
New York City-based Cityblock raised $116 million in Series E funding, according to Dealbreaker.
Cityblock offers clinical care, behavioral health care and social care in patients’ homes, virtually and in community-based clinics, and it primarily serves Medicaid and dual-eligible populations.
Cityblock’s AI-powered operating system aggregates physical, behavioral and social health data to provide care teams with predictive insights into members.
Dealbreaker reported that the $116 million round supported Cityblock’s acquisition of Homeward Health, which it described as a rural healthcare provider.
The funding will be used to invest in the combined platform, including optimizing operations, the care model, technology, and data infrastructure.
Happy Health secures $75 million to validate smart ring and expand beyond sleep
Happy Health secured $75 million in funding, according to Dealbreaker.
Happy Health offers an FDA-cleared smart ring for at-home diagnosis of obstructive sleep apnea, and it also provides treatment management and daily sleep health measurements.
Happy Health’s platform uses continuous health data and AI to create a personalized baseline for each patient, which the company says helps doctors identify meaningful changes in their health.
Sleep is Happy Health’s first focus area, but Dealbreaker reported the company plans to expand into other areas in the future.
Dealbreaker said the $75 million round was from ARCH Venture Partners and OpenLoop.
The financing will help Happy Health accelerate the clinical validation of its technology and build the infrastructure to expand beyond sleep.
Flagler Health raises $50 million Series B led by Bessemer Venture Partners
New York City-based Flagler Health raised $50 million in Series B funding, according to Dealbreaker.
Flagler Health is an AI-native operating system for musculoskeletal care, and it helps MSK practices run more efficiently and better manage patients between visits.
Dealbreaker reported that Flagler supports thousands of providers across 36 states.
The Series B round was led by Bessemer Venture Partners, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners, and Offscript.
In total, Flagler Health has raised $63 million, according to Dealbreaker.
The financing will help Flagler scale across the country, according to the announcement cited by Dealbreaker.
Network Bio launches with $50 million to build disease-specific AI models
Palo Alto, California-based Network Bio launched with $50 million in funding, according to Dealbreaker.
Network Bio is a biotechnology company building disease-specific AI models based on human biological data.
Dealbreaker reported that Network Bio collaborates with academic medical centers and leverages its technology to accelerate diagnostics, biomarker discovery, and drug development.
The $50 million raise was from Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital, according to Dealbreaker.
The funding will be used to expand Network Bio’s life science platform, according to the announcement cited by Dealbreaker.
Widely known context: Series funding labels such as Series B and Series E typically indicate progressively later stages of private-company fundraising.
Widely known context: Venture capital rounds are often disclosed publicly through company announcements and media reporting.
